Navigation Links
BioMarin to Present at the William Blair Growth Stock Conference

NOVATO, Calif., June 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the William Blair Growth Stock Conference in Chicago on Wednesday, June 15, 2011 at 10:00 a.m. CT.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website,  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin to Present at the Jefferies Global Healthcare Conference
2. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
3. BioMarin Announces First Quarter 2011 Financial Results
4. BioMarin to Present at the Deutsche Bank Healthcare Conference
5. BioMarin to Present at the Barclays Global Healthcare Conference
6. BioMarin to Present at the Cowen Health Care Conference
7. BioMarin to Present at the Citi Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
9. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
10. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
11. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015 CIVCO Medical ... technology at the Radiological Society of ... Chicago November 29 – December ... designed to offer customers unrivaled versatility, enhanced user ... --> ...
(Date:11/27/2015)... -- --> --> ... potential to save costs, improve treatment quality and accelerate ... exploited as yet. Here, particular emphasis is placed on ... tablet or directly at the patients, bedside. ... -->      (Photo: ) ...
(Date:11/27/2015)... 2015 Research and Markets ( ) ... Devices Market 2015-2019" report to their offering. ... this report, the author the present scenario and growth ... To calculate the market size, the report considers revenue ... Hormonal IUDs and copper IUDs. The report forecasts the ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic Analog Distortion ... tool designed specially for Final Cut Pro X. FCPX users can ... easy-to-use modification controls. Destoying and creating chaotic distortion is now quick and simple, ...
(Date:11/28/2015)... , ... November 28, 2015 , ... Safe storage for ... of two inventors, one from Lakewood, New Jersey and the other from Bradley Beach, ... patent-pending PROTECTOR to save the expense of having to replace NuvaRings more often than ...
(Date:11/27/2015)... Canada (PRWEB) , ... November 28, 2015 , ... There ... do we outperform our billings from last year? , This question has not been ... organizations are coming to the retirement age and the younger workforce don’t share the ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed ... As people age, more care is needed, especially with Alzheimer’s, dementia and other ... are being overworked. The forgotten part of this equation: 80 percent of medical ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced ... offering customers 10% off of their purchase of lice treatment product. In addition, customers ... According to a company spokesperson. “Finding lice is a sure way to ruin the ...
Breaking Medicine News(10 mins):